Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track INDV with free AI briefings, catalyst countdowns, and dilution alerts.

INDV · Supernus, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$305M Cash on Hand
CF+ Cash Runway
Follow INDV by email Get an email when INDV reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about INDV, unsubscribe in one click. Privacy

📣 What INDV Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Buprenorphine
FDA approved Nov 2017 · Sublocade
Opioid Dependence Phase 4 · NCT02038790 Completed
Buprenorphine Hydrochloride
FDA approved Dec 1981 · Buprenex (discontinued)
Opiate Dependence Phase 4 · NCT00605033 Completed
Buprenorphine Hydrochloride, Naloxone… Hepatic Failure Phase 4 · NCT01846455 Completed
Transmucosal Buprenorphine Moderate to Severe Opioid-use Disorder Phase 4 · NCT04995029 Completed
Naloxone Opiate Dependence Phase 4 · NCT00605033 Completed
Promethazine Hepatic Failure Phase 4 · NCT01846455 Completed
PERSERIS Schizophrenia Phase 4 · NCT03978832 Completed
RBP-7000 Schizophrenia Phase 3 · NCT02109562 Completed
Intranasal challenge drug Heroin Dependence Phase 3 · NCT01760473 Completed
RBP-6000 Opioid Use Disorder Phase 3 · NCT02896296 Completed
XP19986 CR GERD Phase 2 · NCT00838396 Completed
Arbaclofen Placarbil Alcohol Use Disorder Phase 2 · NCT02511886 Completed
RBP-8000 100 mg Opioid Dependence Phase 2 · NCT01846481 Completed
RBP-6300 Opioid Related Disorder Phase 2 · NCT01582347 Completed
Buprenorphine hydrochloride fast dissolving… Opioid Dependency Phase 2 · NCT01075971 Completed
INDV-6001 Moderate to Severe Opioid Use Disorder Phase 2 · NCT06576843 Completed

Also used in these trials (approved or third-party drugs, not INDV's own candidates): Risperidone, Buprenorphine And Naloxone, Midazolam Hydrochloride, Ondansetron - Parts A + B.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

INDV holds $305M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INDV files for a raise →

👥 Who Owns INDV

Insiders 4.4% Other 5%+ holders 5.4% Institutions (463 holders) 59.7% Public and other holders 30.5%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 17,806,183 15.09% 2025-12-31
Vanguard Portfolio Management Institution (13G, 5%+) 7,994,836 6.77% 2026-03-31
Vanguard Capital Management Institution (13G, 5%+) 6,523,720 5.53% 2026-03-31
Millennium Management LLC 5%+ holder (13G) 6,343,651 5.37% 2026-09-23
Jack A. Khattar
Chief Executive Officer, Director · +4.00M options
Insider 3,413,555 2.89% 2026-11-02
Joseph Ciaffoni
Chief Executive Officer, Director
Insider 790,330 0.67% 2026-06-22
Ryan Preblick
Chief Financial Officer
Insider 284,751 0.24% 2026-06-08
Christian Heidbreder
Chief Scientific Officer
Insider 209,337 0.18% 2026-07-10
Jeffrey W Burris
Chief Legal Officer
Insider 71,518 0.06% 2026-03-03
Georges Gemayel
Director · +123,818 options
Insider 42,009 0.04% 2026-11-02
Carrolee Barlow
Director · +116,987 options
Insider 41,652 0.04% 2026-11-02
Patrick A Barry
Chief Commercial Officer
Insider 31,380 0.03% 2026-02-10

Share count 118,035,272 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full INDV picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INDV and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.